Tag Archives: drug safety

Safety Trumps Access to Pain Meds for FDA

By Guest Blogger | Published: April 17, 2013
By Jill Wechsler, Washington Correspondent. The Food and Drug Administration has come down on the side of reducing abuse of opoid medications, over encouraging wider availability of low-cost painkiller meds. The agency decided to block generic versions of the original OxyContin formulation, which is fairly easy to manipulate by illegal users. The aim is to help [...]
Posted in Guest Blog, Op-Ed, Regulatory, Safety, healthcare | Also tagged , , | Leave a comment

"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure

By Jill Wechsler | Published: April 10, 2013
“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler. Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an escalating [...]
Posted in Guest Blog, Op-Ed, Regulatory, Safety, Strategy, healthcare, pricing | Also tagged , , , | 1 Comment

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged , , , , , , , , , , , , | 1 Comment

Combating Opioid Abuse With Science

By Ben Comer | Published: February 23, 2012
So far, the creative approaches industry has taken to develop tamper-resistant and abuse-deterrent opioid drugs have been largely matched by the ingenuity of those users who manage to tamper with and abuse those same formulations.
Posted in FDA, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , | 3 Comments

Memo to President Obama on Reforming FDA

By Peter Pitts | Published: January 21, 2009
In recent weeks, the incoming Obama administration has solicited input from across the policy community as it begins to shape priorities for its forthcoming term. As a former FDA official, I was honored to be asked for my advice on the pharma industry. Demand for drugs is on the rise, yet FDA remains undermanned, underfunded, and [...]
Posted in Regulatory | Also tagged , , , , , | Leave a comment